Health Care • Biotechnology: Pharmaceutical Preparations
$1.02 ▲ +0.00
(0.00%)
MKT CAP: $43.5M • VOL: 1.48M
52W L $1 52W H $6
ROARABLE / RQD
D- • 40/100
PIOTROSKI
1 / 9
ANVS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$29.7M | -$26.7M | -$45.0M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$28.9M | -$24.6M | -$56.2M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$25.6M | -$21.9M | -$40.0M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$25.6M | -$21.9M | -$40.0M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $19.5M | $10.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $16.9M | $9.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ANVS.